BeiGene (BGNE) Stock Price, News & Analysis

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BGNE shares.
View BGNE analyst ratings or view top-rated stocks.

10 Wall Street research analysts have issued 12 month price targets for BeiGene's stock. Their BGNE share price targets range from $161.00 to $345.00. On average, they anticipate the company's stock price to reach $251.93 in the next twelve months. This suggests a possible upside of 76.6% from the stock's current price.
View analysts price targets for BGNE or view top-rated stocks among Wall Street analysts.

BeiGene's stock was trading at $180.36 at the beginning of the year. Since then, BGNE shares have decreased by 20.9% and is now trading at $142.67.
View the best growth stocks for 2024 here.

BeiGene saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 1,830,000 shares, an increase of 17.3% from the May 31st total of 1,560,000 shares. Based on an average daily trading volume, of 175,500 shares, the days-to-cover ratio is presently 10.4 days.
View BeiGene's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our BGNE earnings forecast.

BeiGene, Ltd. (NASDAQ:BGNE) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($2.41) EPS for the quarter, beating analysts' consensus estimates of ($3.07) by $0.66. The firm had revenue of $751.70 million for the quarter, compared to the consensus estimate of $670.09 million. BeiGene had a negative net margin of 28.39% and a negative trailing twelve-month return on equity of 21.70%. The business's revenue for the quarter was up 67.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($3.34) earnings per share.

ETFs with the largest weight of BeiGene (NASDAQ:BGNE) stock in their portfolio include Morningstar US Small Growth (MSGR), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Tema Oncology ETF (CANC), Virtus LifeSci Biotech Products ETF (BBP), Global X Aging Population ETF (AGNG), iShares Biotechnology ETF (IBB) and Invesco Nasdaq Biotechnology ETF (IBBQ).

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

BeiGene (BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.